

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S12–S13
S13
patients. Other compounds such as naltrexone showed similar
effects in smaller trials but are not approved for reduction. More
studies testing further compounds are underway.
Conclusions
This new approach has the potential to lower the
barriers which to date prevent many patients from accepting
treatment for their alcohol problems. Two research questions war-
rant further study: (1) does the reduction in alcohol consumption
translate into health and other benefits, and (2) are there specific
subgroups of patients who benefit more than others. Preliminary
answers will be given in the lecture.
Disclosure of interest
The author has not supplied his declaration
of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.805